178 related articles for article (PubMed ID: 26403403)
21. ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1).
Mato E; González C; Moral A; Pérez JI; Bell O; Lerma E; de Leiva A
J Mol Endocrinol; 2014 Jun; 52(3):289-300. PubMed ID: 24643400
[TBL] [Abstract][Full Text] [Related]
22. RASSF10 is Epigenetically Inactivated and Suppresses Cell Proliferation and Induces Cell Apoptosis by Activating the p53 Signalling Pathway in Papillary Thyroid Carcinoma Cancer.
Fan C; Wang W; Jin J; Yu Z; Xin X
Cell Physiol Biochem; 2017; 41(3):1229-1239. PubMed ID: 28268222
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer.
Chou CK; Liu RT; Kang HY
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28294980
[TBL] [Abstract][Full Text] [Related]
24. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
[TBL] [Abstract][Full Text] [Related]
25. Columnar cell variant of papillary thyroid carcinoma: a study of 10 cases with emphasis on CDX2 expression.
Sujoy V; Pinto A; Nosé V
Thyroid; 2013 Jun; 23(6):714-9. PubMed ID: 23488912
[TBL] [Abstract][Full Text] [Related]
26. Gene expression in poorly differentiated papillary thyroid carcinomas.
Fluge Ø; Bruland O; Akslen LA; Lillehaug JR; Varhaug JE
Thyroid; 2006 Feb; 16(2):161-75. PubMed ID: 16676402
[TBL] [Abstract][Full Text] [Related]
27. Differential Expression of Sumoylation Enzymes SAE1, U BA2, UBC9, PIAS1 and RanBP2 in Major Ocular Tissues of Mouse Eye.
Nie Q; Yang L; Qing W; Xie J; Gong X; Chen H; Gan Y; Wang L; Xiang JW; Xiao Y; Chen Z; Li DW
Curr Mol Med; 2018; 18(6):376-382. PubMed ID: 30479214
[TBL] [Abstract][Full Text] [Related]
28. Vascular invasion is an independent prognostic factor for distant recurrence-free survival in papillary thyroid carcinoma: a matched-case comparative study.
Cao J; Hu JL; Chen C; Wang QL; Fang XH; Zhang Y; Ge MH
J Clin Pathol; 2016 Oct; 69(10):872-7. PubMed ID: 27010434
[TBL] [Abstract][Full Text] [Related]
29. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
[TBL] [Abstract][Full Text] [Related]
30. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
[TBL] [Abstract][Full Text] [Related]
31. Development of prognostic signatures for intermediate-risk papillary thyroid cancer.
Brennan K; Holsinger C; Dosiou C; Sunwoo JB; Akatsu H; Haile R; Gevaert O
BMC Cancer; 2016 Sep; 16(1):736. PubMed ID: 27633254
[TBL] [Abstract][Full Text] [Related]
32. Roles of phosphatidylinositol 3-kinase regulatory subunit alpha, activator protein-1, and programmed cell death 4 in diagnosis of papillary thyroid carcinoma.
Chen X; Wu W; Chen X; Gong X
Tumour Biol; 2016 May; 37(5):6519-26. PubMed ID: 26637226
[TBL] [Abstract][Full Text] [Related]
33. Candidate agents for papillary thyroid cancer identified by gene expression analysis.
Zhu W; Li C; Ai Z
Pathol Oncol Res; 2013 Jul; 19(3):597-604. PubMed ID: 23519608
[TBL] [Abstract][Full Text] [Related]
34. Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome.
Yun JY; Kim YA; Choe JY; Min H; Lee KS; Jung Y; Oh S; Kim JE
J Clin Pathol; 2014 Feb; 67(2):125-33. PubMed ID: 23986551
[TBL] [Abstract][Full Text] [Related]
35. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
[TBL] [Abstract][Full Text] [Related]
36. Survival Analysis of Papillary Thyroid Carcinoma in Relation to Stage and Recurrence Risk: A 20-Year Experience in Pakistan.
Hassan A; Razi M; Riaz S; Khalid M; Nawaz MK; Syed AA; Bashir H
Clin Nucl Med; 2016 Aug; 41(8):606-13. PubMed ID: 27124680
[TBL] [Abstract][Full Text] [Related]
37. Increased Small Ubiquitin-like Modifier-Activating Enzyme SAE1 Promotes Hepatocellular Carcinoma by Enhancing mTOR SUMOylation.
Chen Y; Peng W; Tao Q; Li S; Wu Z; Zhou Y; Xu Q; Shu Y; Xu Y; Shao M; Chen M; Shi Y
Lab Invest; 2023 Jan; 103(1):100011. PubMed ID: 36748193
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of BRAF mutation in thyroid papillary cancer.
Fernandez IJ; Piccin O; Sciascia S; Cavicchi O; Repaci A; Vicennati V; Fiorentino M
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):919-25. PubMed ID: 23482475
[TBL] [Abstract][Full Text] [Related]
39. CD1a-positive dendritic cell density predicts disease-free survival in papillary thyroid carcinoma.
Hilly O; Rath-Wolfson L; Koren R; Mizrachi A; Hamzany Y; Bachar G; Shpitzer T
Pathol Res Pract; 2015 Sep; 211(9):652-6. PubMed ID: 26073685
[TBL] [Abstract][Full Text] [Related]
40. High expression of metadherin correlates with malignant pathological features and poor prognostic significance in papillary thyroid carcinoma.
Li WF; Wang G; Zhao ZB; Liu CA
Clin Endocrinol (Oxf); 2015 Oct; 83(4):572-80. PubMed ID: 25418110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
